Floatz logo

Kite-363

Relapsed and/or Refractory B-cell Lymphoma

Kite, A Gilead CompanyCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

316 Active assets in the Relapsed and/or Refractory B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Kite-363 is also rated in:

chronic inflammatory demyelinating polyradiculoneuropathyDormant
CC
Indicative ·
43 / 100
View asset →
myasthenia gravisDormant
CC
Indicative ·
43 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →